Solana Company Stock Price, News & Analysis

Helius Medical Technologies (Nasdaq:HSDT) has launched a new online training module for physical therapists aimed at treating gait deficits in multiple sclerosis (MS) patients. This shift from in-person training to an online format allows therapists to complete the training in under three hours, significantly increasing accessibility. Currently, 55 therapists in the U.S. and 20 in Canada are queued for training. Helius aims to standardize training and enhance the delivery of PoNS Therapy, intended for individuals with mild to moderate MS symptoms.

Helius Medical Technologies (Nasdaq: HSDT) presented a poster on the effectiveness of its Portable Neuromodulation Stimulator (PoNS) Therapy at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting. The study demonstrated significant gait improvement in patients with multiple sclerosis (MS) after two weeks of therapy. The poster was nominated for the prestigious Labe C. Scheinberg Award, highlighting its impact in advancing MS care. Helius plans to gather further evidence through its Therapeutic Experience Program, reinforcing its commitment to improving neurological wellness.

Helius Medical Technologies (Nasdaq:HSDT) launched a Patient Therapy Access Program (PTAP) to improve access to its Portable Neuromodulation Stimulator (PoNS) Therapy for patients with multiple sclerosis (MS). This initiative offers eligible patients reduced pricing for PoNS, which is prescribed for gait deficits due to mild-to-moderate MS symptoms. The program aims to drive adoption of PoNS Therapy and supports data collection for future clinical evidence. PTAP will run until December 31, 2022, enhancing access for first-time users of the therapy.

Helius Medical Technologies (Nasdaq: HSDT) announced a poster presentation at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting from June 1-4, 2022. The highlighted abstract showcases real-world data indicating that translingual neurostimulation can effectively improve gait in multiple sclerosis patients. Chief Medical Officer Antonella Favit-Van Pelt emphasized the benefits of neuromodulation in enhancing walking stability and promoting neuroplasticity. The presentation is scheduled for June 2 at 5:00 p.m. ET, with Helius representatives available to discuss the Portable Neuromodulation Stimulator (PoNS) device at Booth #804.

Helius Medical Technologies (HSDT) announced that its independent directors have approved the issuance of equity awards as part of its 2021 Inducement Plan, effective May 23, 2022. Four new employees, not previously associated with Helius, received options to purchase a total of 21,000 shares at an exercise price of $1.40 each, which reflects the closing stock price on the date of the grant. These options will vest over four years, providing Helius with a strategic advantage in attracting talent while adhering to Nasdaq regulations.

Helius Medical Technologies has expanded its Therapeutic Experience Program (TEP) by adding Shepherd Center in Atlanta as a second Center of Excellence. This multi-center observational trial aims to assess the effectiveness of Portable Neuromodulation Stimulator (PoNS) therapy for gait improvement in patients with multiple sclerosis (MS). Led by Dr. Deborah Backus, the program will provide valuable data on treatment adherence and outcomes, with enrollment expected to begin in Q2 2022.

Helius Medical Technologies (HSDT) reported a 126% increase in Q1 2022 revenue to $190,000, up from $84,000 in Q1 2021. The U.S. commercial launch of PoNS for multiple sclerosis began, with 23 prescriptions written. Operating loss widened to $4.6 million compared to $3.5 million in Q1 2021. Cash used in operations rose to $4.7 million from $2.9 million. The company anticipates being cash flow positive by Q4 2023, projecting sequential revenue growth beyond the first quarter.

Helius Medical Technologies (NASDAQ: HSDT) will release its Q1 2022 financial results on May 12, 2022, before market opening. CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen will lead a conference call to discuss the results and provide insights into Helius' plans for the U.S. commercialization of PoNS®, its first medical device aimed at improving neurological wellness. The call is scheduled for 9:00 a.m. ET, with details available via the webcast.

Helius Medical Technologies (HSDT) announced the fulfillment of the first prescriptions for its Portable Neuromodulation Stimulator (PoNS) therapy aimed at treating gait deficits in multiple sclerosis (MS) patients. Following its commercial launch in the U.S., there have been 19 PoNS prescriptions written, with two patients commencing therapy. The device, previously available in Canada, is marketed on a cash pay basis as the company seeks reimbursement from insurers. This launch marks a significant step in addressing the needs of nearly one million MS patients in the U.S.